JPMorgan Chase & Co. set a €100.00 ($116.28) target price on Merck KGaA (FRA:MRK) in a research note released on Thursday, Borsen Zeitung reports. The brokerage currently has a neutral rating on the healthcare company’s stock.
Other equities analysts also recently issued reports about the stock. DZ Bank reissued a buy rating on shares of Merck KGaA in a report on Wednesday, August 14th. Credit Suisse Group set a €110.00 ($127.91) price target on shares of Merck KGaA and gave the company a buy rating in a report on Friday, September 6th. UBS Group set a €99.00 ($115.12) price target on shares of Merck KGaA and gave the company a neutral rating in a report on Thursday, August 8th. Barclays set a €82.00 ($95.35) price target on shares of Merck KGaA and gave the company a sell rating in a report on Wednesday, August 14th. Finally, Nord/LB set a €94.00 ($109.30) target price on shares of Merck KGaA and gave the stock a neutral rating in a research note on Friday, August 9th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and five have assigned a buy rating to the stock. Merck KGaA presently has an average rating of Hold and an average target price of €100.94 ($117.38).
Shares of MRK stock opened at €99.02 ($115.14) on Thursday. Merck KGaA has a 12-month low of €76.60 ($89.07) and a 12-month high of €115.00 ($133.72). The firm has a 50-day moving average price of €94.83 and a 200 day moving average price of €94.65.
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Featured Story: What Are Cryptocurrencies?
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.